Curanex faces two putative securities class actions over August 2025 IPO disclosures

Curanex Pharmaceuticals Inc

Daymond Morales filed Action 1 on July 23, 2026 in New York Supreme Court (Index 159271/2026) against Curanex and underwriters Dominari, Pacific Century and Revere.
Robert Lovett filed Action 2 on Sept. 14, 2026 (Index 655238/2026) against Curanex, its former CFO, directors, auditor and the same IPO underwriters.
Both suits allege Sections 11 and 12(a)(2) violations over the August 2025 IPO offering documents, citing stock-price manipulation risks and underwriter due-diligence and AML deficiencies.
Curanex says neither complaint asserts fraud against it, intends to defend vigorously; response deadlines are Nov. 15, 2026 for Morales and Dec. 11, 2026 for Lovett.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.